1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination has been researched along with atropine in 2 studies
Studies (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Trials (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Recent Studies (post-2010) (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
---|---|---|---|---|---|
20 | 0 | 0 | 26,711 | 1,259 | 1,697 |
Protein | Taxonomy | 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination (IC50) | atropine (IC50) |
---|---|---|---|
cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
HUGHES, JL; WILSON, WP | 1 |
KISSEL, WA | 1 |
2 other study(ies) available for 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination and atropine
Article | Year |
---|---|
OBSERVATIONS ON THE EFFECTS OF JB-329 (DITRAN) ON THE ELECTROENCEPHALOGRAM OF MAN.
Topics: Antisocial Personality Disorder; Anxiety; Anxiety Disorders; Atropine; Bipolar Disorder; Depression; Drug Combinations; Drug Therapy; Electroencephalography; Glycolates; Hallucinogens; Mental Disorders; Piperidines; Psychoses, Alcoholic; Psychotic Disorders; Pyrrolidines; Schizophrenia; Toxicology | 1964 |
Atropine-like coma with Ditran therapy.
Topics: Atropine; Coma; Depression; Depressive Disorder; Drug Combinations; Glycolates; Hallucinogens; Humans; Piperidines; Pyrrolidines | 1962 |